Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Abirawel
Abirawel (Abiraterone Acetate 500 mg) is a hormonal therapy designed for the treatment of advanced prostate cancer. By targeting androgen biosynthesis, it helps slow cancer progression and improve survival outcomes.
Uses of Abirawel
Metastatic castration-resistant prostate cancer (mCRPC) in patients previously treated with chemotherapy.
Metastatic high-risk castration-sensitive prostate cancer (mCSPC) in combination with androgen deprivation therapy (ADT).
Benefits of Abirawel
Effectively reduces androgen levels to slow prostate cancer progression.
Prolongs survival and delays disease progression.
Non-invasive oral therapy with proven clinical benefits.
Enhances quality of life by controlling cancer-related symptoms.
Mechanism of Action of Abirawel
Abiraterone Acetate inhibits the CYP17 enzyme complex, blocking testosterone and androgen synthesis in the testes, adrenal glands, and prostate tumor tissue. This leads to a significant reduction in tumor growth and cancer cell proliferation.